Novo Nordisk sues Eli Lilly over ‘deliberately false’ weight-loss drug ads
Danish group claims rival used outdated data to support claims that its products were more effective than Wegovy…
Read More
Select Page
by Larisa Schroeder | Jul 21, 2026 | Business | 0 |
Danish group claims rival used outdated data to support claims that its products were more effective than Wegovy…
Read Moreby Jeanice Roberie | Nov 15, 2024 | Health & Medical | 0 |
LONDON (Reuters) -Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections. The company declined to comment on the timeline. “Globally (human insulin pens) will be phased out over time and human insulin will be available
Read More
Recent Comments